In this study, we explored the activity of mTOR inhibition in pancreatic cancer with the goals to determine whether the observed activity warranted clinical development and to prioritise biomarkers that could be incorporated in clinical trials. This evidence concerns the gene MTOR and familial pancreatic carcinoma.